Pro12Ala Polymorphism of the Peroxisome ProliferatorActivated Receptor-γ Gene is Associated With Metabolic Syndrome and Surrogate Measures of Insulin Resistance in Healthy Men: Interaction With Smoking Status

Background: The Pro12Ala polymorphism (rs1801282), a nonsynonymous substitution of peroxisome proliferator-activated receptor-γ (PPARG), has been robustly associated with type 2 diabetes. However, its role in metabolic syndrome (MetS) remains poorly understood. The associations among rs1801282, MetS...

Full description

Saved in:
Bibliographic Details
Published in:Circulation Journal 2009, Vol.73(11), pp.2118-2124
Main Authors: Tellechea, Mariana L., Aranguren, Florencia, Pérez, María Silvia, Cerrone, Gloria E., Frechtel, Gustavo D., Taverna, Mariano J.
Format: Article
Language:English
Subjects:
Adolescent
Adult
Aged
Alleles
Amino Acid Substitution
Argentina
Blood Donors
Cross-Sectional Studies
Gene Frequency
Genetics
Humans
Inflammation
Insulin resistance
Insulin Resistance - genetics
Male
Metabolic syndrome
Metabolic Syndrome - genetics
Middle Aged
Obesity - genetics
Overweight - genetics
Peroxisome proliferator-activated receptor-γ Pro12Ala polymorphism
Polymorphism, Single Nucleotide
PPAR gamma - genetics
Risk Factors
Smoking - genetics
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background: The Pro12Ala polymorphism (rs1801282), a nonsynonymous substitution of peroxisome proliferator-activated receptor-γ (PPARG), has been robustly associated with type 2 diabetes. However, its role in metabolic syndrome (MetS) remains poorly understood. The associations among rs1801282, MetS and surrogate measures of insulin resistance (IR) were investigated in the present study. Methods and Results: A cross-sectional population-based survey of 572 unrelated healthy male Argentinian blood donors with normal findings on medical examination and not taking any medication was conducted. MetS was assessed using the National Cholesterol Education Program/Adult Treatment Panel III (NCEP/ATP III) criteria, and the HOMA-IR, and QUICKI were calculated. Genotyping of rs1801282 was performed using RFLP-PCR. The prevalence of MetS was 26.2%. The Pro/Ala genotype (and the Ala12 allele) was associated with a high risk for MetS (odds ratio (OR) 1.67 [95% confidence interval (CI) 1.03-2.72], P=0.0394). This was highlighted among nonsmokers (OR 2.20 [95%CI 1.25-3.88], P=0.0059). ANCOVA confirmed an interaction between smoking status and this association (P=0.031). Ala12 carriers had a higher waist circumference than noncarriers (P=0.0065). Among nonsmokers, surrogates of IR, such as HOMA-IR, were significantly higher in Ala12 carriers than in noncarriers (P
ISSN:1346-9843
1347-4820
DOI:10.1253/circj.CJ-09-0320